Abstract
FDA: “all labels and other written, printed or graphic matter upon any article or any of its containers or wrappers – or accompanying such article”; labelling is part of the manufacturing process and subject to GMP; reconciliation of the quantities of labels issued, used and returned is necessary; a label representative of those used should be included in the batch production record; see also misbranded drug; labelling of investigational drug samples for clinical trials requires, according to EC guidelines of good clinical practice (III), the following minimal amount of information: “For clinical trial”, name of the responsible physician (investigator), identification-code of the trial, substance or patient code, dosage form, quantity, directions for use, storage conditions, expiry/retest date, producer, contact details (importer if manufacturer is outside the EU), “keep out of reach of children” (if taken home); for clinical trials of medicinal products for use before and during pregnancy: within the EC the following categories for labelling are used: A – product has been assessed, no harmful effects are known; B1 – safety not established, animal studies do not indicate harmful effects; B2 – safety not established, animal studies are insufficient to assess safety; B3 – safety not established, animal studies have shown reproductive toxicity; C – product does not increase spontaneous incidence of birth defects, but has potential hazardous pharmacological effects with respect to the course of pregnancy; D – product is known or suspect to cause birth defects and/or irreversible adverse effects on pregnancy outcome; it may also have potential hazardous pharmacological effects with respect to the course of pregnancy; see also adverse drug experience, blue box requirements, investigational drug labelling, label text, manufacture, pregnancy and lactation labelling.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2017 Springer International Publishing AG
About this chapter
Cite this chapter
Nahler, G. (2017). L. In: Dictionary of Pharmaceutical Medicine. Springer, Cham. https://doi.org/10.1007/978-3-319-50669-2_12
Download citation
DOI: https://doi.org/10.1007/978-3-319-50669-2_12
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-50668-5
Online ISBN: 978-3-319-50669-2
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)